Mohammad F Madhoun1, Tauseef Ali, William M Tierney, John T Maple. 1. Division of Digestive Diseases and Nutrition, University of Oklahoma Health Sciences Center, Oklahoma City, USA; Veteran Affairs Medical Center, Oklahoma City, USA.
Abstract
BACKGROUND AND AIM: Anti-spasmodic drugs may facilitate mucosal inspection during colonoscopy. The impact of hyoscine N-butylbromide (HBB) on polyp detection rate (PDR) and adenoma detection rate (ADR) is unclear. METHODS: We conducted a reproducible literature search of multiple databases. Two reviewers independently compared manuscripts for PDR, ADR, advanced adenoma detection rate (AADR), and rates of complications. Pooling was conducted by fixed-effects and random-effects models. Relative risk (RR) estimates were calculated (95% confidence interval). I(2) index assessed heterogeneity. RESULTS: Patient demographics were comparable. The pooled analysis showed a trend toward improving PDR and ADR among the HBB group compared with the placebo group but failed to reach statistical significance, (46% vs 43%, RR = 1.08 [0.94, 1.25], P = 0.27), (31% vs 28%, RR = 1.12 [0.97, 1.29], P = 0.11) respectively. CONCLUSION: HBB during colonoscopy may provide marginal improvements in ADR and PDR. However, heterogeneity in the available data precludes firm conclusions at this time.
BACKGROUND AND AIM: Anti-spasmodic drugs may facilitate mucosal inspection during colonoscopy. The impact of hyoscine N-butylbromide (HBB) on polyp detection rate (PDR) and adenoma detection rate (ADR) is unclear. METHODS: We conducted a reproducible literature search of multiple databases. Two reviewers independently compared manuscripts for PDR, ADR, advanced adenoma detection rate (AADR), and rates of complications. Pooling was conducted by fixed-effects and random-effects models. Relative risk (RR) estimates were calculated (95% confidence interval). I(2) index assessed heterogeneity. RESULTS:Patient demographics were comparable. The pooled analysis showed a trend toward improving PDR and ADR among the HBB group compared with the placebo group but failed to reach statistical significance, (46% vs 43%, RR = 1.08 [0.94, 1.25], P = 0.27), (31% vs 28%, RR = 1.12 [0.97, 1.29], P = 0.11) respectively. CONCLUSION:HBB during colonoscopy may provide marginal improvements in ADR and PDR. However, heterogeneity in the available data precludes firm conclusions at this time.
Authors: Colin J Rees; Roisin Bevan; Katharina Zimmermann-Fraedrich; Matthew D Rutter; Douglas Rex; Evelien Dekker; Thierry Ponchon; Michael Bretthauer; Jaroslaw Regula; Brian Saunders; Cesare Hassan; Michael J Bourke; Thomas Rösch Journal: Gut Date: 2016-10-08 Impact factor: 23.059
Authors: Peel Jung; Su B Park; Hyung W Kim; Dae H Kang; Cheol W Choi; Su J Kim; Hyeong S Nam; Dae G Ryu; Joung B Hong; Dong J Kim Journal: Medicine (Baltimore) Date: 2018-06 Impact factor: 1.889